Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/14/22
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/14/22
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging IndustryZacks Investment Research • 03/02/22
Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations OfficerGlobeNewsWire • 02/22/22
Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' NowZacks Investment Research • 02/07/22
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6GlobeNewsWire • 01/31/22
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia AGlobeNewsWire • 11/29/21
Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 11/10/21
Sigilon Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/09/21
Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 08/10/21
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related DiseasesGlobeNewsWire • 07/23/21
Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business DevelopmentGlobeNewsWire • 07/19/21
Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares DropBenzinga • 07/09/21
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia AGlobeNewsWire • 07/09/21
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of DirectorsGlobeNewsWire • 06/16/21
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific OfficerGlobeNewsWire • 06/14/21